Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Pharmaceuticals
- Disease
- Diagnostic
- Proteins
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29372
Actimmune® (interferon gamma-1b) is a bio-engineered interferon gamma, a naturally occurring human protein that acts as a biologic response modifier that stimulates the immune system and has direct effect on various cells in the body.
IPSCIO Record ID: 27553
IPSCIO Record ID: 26724
Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.
IPSCIO Record ID: 7160
Under this Agreement the Licensee has the exclusive License to develop and commercialize Actimmune in the United States and Canada for the treatment and prevention of all human diseases and conditions, including infectious diseases, pulmonary fibrosis and cancer, but excluding arthritis and cardiac and cardiovascular diseases and conditions.
In Japan, the Licensee have the exclusive License rights to commercialize Actimmune for the treatment and prevention of all infectious diseases caused by fungal, bacterial or viral agents, including in patients with CGD or osteoporosis.
The Licensee also has a non-exclusive License to make or have made, Actimmune for clinical and commercial purposes within our field of use in the United States and Canada.
IPSCIO Record ID: 159507
The Board of Directors of Licensee and the Company have authorized amending the Royalty Agreement in consideration of the elimination of indebtedness of Licensee to the Company and of the promises and covenants set forth herein and for other good and valuable consideration, the parties agree to the following but not limited to; modifying the royalty section, extended the term, and rescinded a section.
Interferon shall mean and include a protein substance currently characterized as a viral neutralizing protein substance, whether produced naturally by lymphocytes, connective (fibroblast) tissue, including alpha, beta, and gamma interferon, and whether produced naturally or through a genetic engineering process.
Transfer Factor shall mean and include any lymphokine which exhibits specific biological activity for the protection of the body from viruses which is now recognized as mobilizing the natural immunological defense system of the body, whether the transfer factor is produced naturally from lymphokines or from other natural substances or whether produced through genetic engineering technology.
